Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank.

Msaouel P, La Rosa S, Abel EJ, Albiges L, Barata PC, Berg SA, Braun DA, Brugarolas J, Campbell MT, Carlo MI, Coleman K, Cost NG, Das A, Desai A, Dizman N, Drago D, Economides M, Geynisman DM, Griffith M, Hall T, Henske EP, Jonasch E, Khanna P, Kotecha RR, Luckenbaugh A, Maranchie JK, Master V, May AM, Motzer RJ, Ornstein MC, Ortiz MV, Pal SK, Perez JR, Rini B, Shapiro DD, Shuch BM, Singer AE, Singer EA, Stadler WM, Staehler M, Tannir NM, Vaishampayan UN, Xu W, Yip W, Zacharias NM, Voss MH

Open source

DOI
10.1016/j.urolonc.2026.07.035
Published
2026 Sep 12
Container
Urologic oncology
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.urolonc.2026.07.035,
  title = {Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank.},
  author = {Msaouel P and La Rosa S and Abel EJ and Albiges L and Barata PC and Berg SA and Braun DA and Brugarolas J and Campbell MT and Carlo MI and Coleman K and Cost NG and Das A and Desai A and Dizman N and Drago D and Economides M and Geynisman DM and Griffith M and Hall T and Henske EP and Jonasch E and Khanna P and Kotecha RR and Luckenbaugh A and Maranchie JK and Master V and May AM and Motzer RJ and Ornstein MC and Ortiz MV and Pal SK and Perez JR and Rini B and Shapiro DD and Shuch BM and Singer AE and Singer EA and Stadler WM and Staehler M and Tannir NM and Vaishampayan UN and Xu W and Yip W and Zacharias NM and Voss MH},
  year = {2026},
  journal = {Urologic oncology},
  doi = {10.1016/j.urolonc.2026.07.035},
  url = {https://doi.org/10.1016/j.urolonc.2026.07.035}
}

RIS

TY  - JOUR
TI  - Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank.
AU  - Msaouel P
AU  - La Rosa S
AU  - Abel EJ
AU  - Albiges L
AU  - Barata PC
AU  - Berg SA
AU  - Braun DA
AU  - Brugarolas J
AU  - Campbell MT
AU  - Carlo MI
AU  - Coleman K
AU  - Cost NG
AU  - Das A
AU  - Desai A
AU  - Dizman N
AU  - Drago D
AU  - Economides M
AU  - Geynisman DM
AU  - Griffith M
AU  - Hall T
AU  - Henske EP
AU  - Jonasch E
AU  - Khanna P
AU  - Kotecha RR
AU  - Luckenbaugh A
AU  - Maranchie JK
AU  - Master V
AU  - May AM
AU  - Motzer RJ
AU  - Ornstein MC
AU  - Ortiz MV
AU  - Pal SK
AU  - Perez JR
AU  - Rini B
AU  - Shapiro DD
AU  - Shuch BM
AU  - Singer AE
AU  - Singer EA
AU  - Stadler WM
AU  - Staehler M
AU  - Tannir NM
AU  - Vaishampayan UN
AU  - Xu W
AU  - Yip W
AU  - Zacharias NM
AU  - Voss MH
PY  - 2026
JO  - Urologic oncology
DO  - 10.1016/j.urolonc.2026.07.035
UR  - https://doi.org/10.1016/j.urolonc.2026.07.035
ER  -

APA

P, M., S, L. R., EJ, A., L, A., PC, B., SA, B., DA, B., J, B., MT, C., MI, C., K, C., NG, C., A, D., A, D., N, D., D, D., M, E., DM, G., M, G., T, H., EP, H., E, J., P, K., RR, K., A, L., JK, M., V, M., AM, M., RJ, M., MC, O., MV, O., SK, P., JR, P., B, R., DD, S., BM, S., AE, S., EA, S., WM, S., M, S., NM, T., UN, V., W, X., W, Y., NM, Z., & MH, V. (2026). Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank.. Urologic oncology. https://doi.org/10.1016/j.urolonc.2026.07.035

Source records